Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686918 | 0.78 | L3MBTL1 (0.51) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL3463008 | 0.77 | MRGPRX1 (0.52) | MEN1KMT2ASSTR5NPC1RAB9A | |
| SCHEMBL3463524 | 0.73 | MAPT (0.55) | MEN1KMT2ASSTR5NPC1RAB9A | |
| SCHEMBL3948639 | 0.72 | PCSK9 (0.54) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL12749660 | 0.70 | MEN1 (0.62) | MEN1KMT2ASSTR5NPC1RAB9A | |
| SCHEMBL6095764 | 0.70 | KMT2A (0.63) | MEN1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6095767 | 0.70 | KMT2A (0.63) | MEN1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL9781400 | 0.69 | MEN1 (0.70) | MEN1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL9119369 | 0.69 | KMT2A (0.70) | MEN1KMT2AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL9119354 | 0.69 | KMT2A (0.70) | MEN1KMT2AMAPTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468367-B2 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-12-23 | — | — | US | claimed |
| EP-1456203-B1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2008-08-20 | — | — | EP | claimed |
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2005-07-21 | — | — | US | claimed |
| US-7468367-B2 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-12-23 | — | — | US | disclosed |
| EP-1456203-B1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2005-07-21 | — | — | US | disclosed |
| EP-1456203-A1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003051872-A1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | HCRTR2, HCRTR1, GRPR | MEN1 593/4885KMT2A 834/4885SSTR5 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.